Delaney Dennis R Raises Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Delaney Dennis R boosted its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 57.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 21,360 shares of the company's stock after purchasing an additional 7,820 shares during the period. Delaney Dennis R's holdings in Novo Nordisk A/S were worth $1,483,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the stock. BIP Wealth LLC increased its stake in Novo Nordisk A/S by 3.9% in the 4th quarter. BIP Wealth LLC now owns 3,642 shares of the company's stock worth $313,000 after purchasing an additional 138 shares during the period. Xponance Inc. increased its stake in Novo Nordisk A/S by 4.9% in the 4th quarter. Xponance Inc. now owns 3,156 shares of the company's stock worth $271,000 after purchasing an additional 146 shares during the period. 180 Wealth Advisors LLC increased its stake in Novo Nordisk A/S by 3.6% in the 1st quarter. 180 Wealth Advisors LLC now owns 5,014 shares of the company's stock worth $348,000 after purchasing an additional 173 shares during the period. LRI Investments LLC increased its stake in Novo Nordisk A/S by 1.4% in the 4th quarter. LRI Investments LLC now owns 13,060 shares of the company's stock worth $1,123,000 after purchasing an additional 176 shares during the period. Finally, Beacon Financial Group grew its position in shares of Novo Nordisk A/S by 6.5% in the 1st quarter. Beacon Financial Group now owns 2,884 shares of the company's stock worth $200,000 after buying an additional 177 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on NVO shares. Hsbc Global Res upgraded Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. BMO Capital Markets reiterated a "market perform" rating and issued a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Dbs Bank lowered Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Wall Street Zen upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Saturday, June 14th. Finally, Guggenheim lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of "Hold" and an average price target of $112.00.

Novo Nordisk A/S Stock Up 1.3%

Novo Nordisk A/S stock traded up $0.94 during mid-day trading on Friday, hitting $71.67. The company had a trading volume of 7,345,265 shares, compared to its average volume of 7,144,964. The company has a current ratio of 0.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.70. The stock's 50 day moving average price is $70.67 and its two-hundred day moving average price is $73.80. Novo Nordisk A/S has a 12 month low of $57.00 and a 12 month high of $139.74. The company has a market capitalization of $320.00 billion, a PE ratio of 21.20, a price-to-earnings-growth ratio of 1.36 and a beta of 0.64.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.92. The firm had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.